MENU

PPBT Purple Biotech Ltd. Forecast, Technical & Fundamental Analysis

Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals... Show more

A.I.Advisor
Nov 15, 2026

Purple Biotech (PPBT) Stock Forecast: Can the CAPTN-3 Platform Carry the Pipeline Into the Clinic?

Key Takeaways

  • The single most important near-term catalyst is advancing IM1240, the lead tri-specific antibody from the CAPTN-3 platform, toward a planned Phase 1 clinical trial, with recent toxicology and manufacturing milestones de-risking the path.
  • Purple Biotech has narrowed its strategy sharply around CAPTN-3, a masked tri-specific antibody platform that engages both T cells and natural killer (NK) cells while using "capping" technology to confine immune activation to the tumor microenvironment.
  • Legacy clinical assets CM24 and NT219 were impaired in late 2025, and their future development now depends on securing a partner or strategic investment, making partnership execution a pivotal swing factor.
  • The company ended 2025 with roughly $9.5 million in cash, which management expects to fund operations into 2027, but additional capital raises or partnering are likely to influence dilution and sentiment.
  • Analyst coverage remains thin; H.C. Wainwright has maintained a Buy rating while revising its price target lower, reflecting both the platform's promise and rising financing and execution uncertainty.
  • As a clinical-stage biotech, PPBT is highly sensitive to the funding environment, regulatory timelines, and broader risk appetite in the biotechnology sector.
  • For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Earnings, explore the dedicated pages for PPBT.
  • To see how automated systems are screening the market right now, explore Trending AI Robots.

Strategic Positioning and Competitive Outlook

Purple Biotech Ltd. is a clinical-stage immunotherapy company headquartered in Rehovot, Israel, focused on next-generation antibody therapies for solid-tumor cancers. Its strategic center of gravity is now the CAPTN-3 platform, which produces "masked" tri-specific antibodies designed to bind a tumor-associated antigen while simultaneously engaging T cells and NK cells. The capping design is intended to keep immune activation localized to the tumor, potentially widening the therapeutic window (the gap between an effective dose and a toxic one) relative to conventional T-cell engagers.

The lead candidate, IM1240, targets the 5T4 antigen, while the second candidate, IM1305, targets TROP2. Both are aimed at solid tumors associated with advanced disease and poor outcomes. Positive preclinical data presented at the ESMO Immuno-Oncology Congress 2025, along with toxicology results showing improved tolerability at doses up to 300-fold higher than a non-capped comparator, support the platform's differentiating thesis. Management has also reported commercially viable manufacturing yields, a meaningful step for a complex multi-valent antibody.

Structurally, the company has concentrated its limited resources on one platform and de-emphasized two clinical-stage assets, CM24 and NT219, whose continued development is contingent on partnering or external funding. This focus simplifies the investment case but also concentrates risk: the near-term valuation narrative now rests largely on the execution of a single preclinical-to-Phase 1 program.

Major Catalysts Ahead

The clearest growth catalyst on the horizon is the planned initiation of a Phase 1 clinical trial for IM1240. Successfully filing an investigational new drug application and dosing the first patient would mark a transition from preclinical promise to clinical validation, a threshold that typically drives re-rating in early-stage biotech. Additional preclinical data disclosures on IM1240 and IM1305 through 2026 could further shape investor sentiment.

Partnership activity is a second pivotal catalyst. Because CM24 (a CEACAM1-blocking antibody) and NT219 (a dual IRS1/2 and STAT3 inhibitor) can only advance with outside capital or a collaborator, any licensing deal or strategic investment would both validate the broader pipeline and reduce financing pressure.

Capital allocation is equally important. With roughly $9.5 million in cash at year-end 2025 and a stated runway into 2027, future equity raises could dilute existing holders but also extend the company's ability to reach clinical milestones.

On analyst sentiment, coverage is limited. H.C. Wainwright has maintained a Buy rating while lowering its 12-month price target in stages, from $34 to $30 and subsequently to $17, a signal of tempered optimism. Consensus ratings across data providers range from "Hold" to "Moderate Buy," and the thin coverage means individual revisions can carry outsized influence on the stock forecast.

Industry and Macroeconomic Forces

Purple Biotech operates at the intersection of two active oncology themes: T-cell engagers and masked (conditionally activated) antibodies. Industry attention to cytokine release syndrome and other immune-related toxicities has increased demand for technologies that promise potency without systemic side effects, a tailwind aligned with CAPTN-3's design.

Macro conditions matter indirectly through the financing channel. Clinical-stage companies without product revenue depend on equity markets, and higher-for-longer interest rates or a risk-off environment can raise the cost of capital and pressure valuations across the biotech sector. Inflation trends influence R&D and manufacturing costs, while the regulatory climate, particularly the U.S. Food and Drug Administration's stance on novel antibody formats, will shape development timelines. Geopolitical considerations tied to the company's Israeli headquarters and operations can also periodically affect execution and investor sentiment.

Trend Prediction Engine

For traders seeking a data-driven read on near-term direction, Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps identify whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. While it does not replace fundamental analysis, it can complement a research workflow focused on the timing and direction of moves. Consider exploring the Trend Prediction Engine to see how its AI-driven signals are currently reading PPBT alongside your own analysis.

2026 Outlook and Long-Term Themes to Watch

Looking into 2026 and beyond, the defining question is whether CAPTN-3 can translate compelling preclinical data into clinical proof of concept. A successful early readout would position the platform as a differentiated player in the crowded but high-value solid-tumor immunotherapy market, while any safety or manufacturing setback could sharply reset expectations given the concentrated pipeline.

Longer-term themes include the evolution of masked-antibody science, where competitors are also pursuing conditionally activated approaches; cost-structure discipline, as a lean organization must stretch limited cash across multi-year clinical development; and capital-allocation priorities, which will hinge on whether management funds IM1240 organically, via partnerships, or through additional equity raises. Regulatory developments governing tri-specific antibody formats and the trajectory of oncology partnership activity will also be important signposts.

Consensus expectations remain modest and thinly covered, and external price targets should be read strictly as analyst projections rather than guarantees. For investors evaluating the future outlook, the key variables are clinical execution, partnering success, and the durability of the company's funding runway, each of which will shape the trajectory of the PPBT stock forecast over the medium term.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

PPBT is expected to report earnings to rise 512.20% to -250 cents per share on February 10

Purple Biotech Ltd. PPBT Stock Earnings Reports
Q4'26
Est.
$-2.51
Q2'26
Missed
by $0.01
Q1'26
Beat
by $0.30
Q4'25
Beat
by $0.33
Q2'24
Beat
by $0.02
The last earnings report on August 07 showed earnings per share of -40 cents, missing the estimate of -40 cents. With 6.40K shares outstanding, the current market capitalization sits at 2.11M.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLNK0.39N/A
+0.51%
Blink Charging Co
LXFR17.360.01
+0.06%
Luxfer Holdings PLC
AMH32.18-0.34
-1.05%
American Homes 4 Rent
HSAI12.59-0.64
-4.84%
Hesai Group American Depositary Share each ADS represents one
SVRE0.41-0.02
-5.03%
SaverOne 2014 Ltd.

PPBT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PPBT has been loosely correlated with SNTI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PPBT jumps, then SNTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PPBT
1D Price
Change %
PPBT100%
+1.79%
SNTI - PPBT
57%
Loosely correlated
-28.68%
ATOS - PPBT
34%
Loosely correlated
-1.55%
BCYC - PPBT
32%
Poorly correlated
+0.63%
APLM - PPBT
31%
Poorly correlated
-5.37%
CCCC - PPBT
27%
Poorly correlated
-4.53%
More
A.I. Advisor
published General Information

General Information

a provider of pharmaceutical drug discovery and development services

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
4 Oppenheimer Street
Phone
+972 39333121
Employees
10
Web
https://www.purple-biotech.com
Purple Biotech (PPBT) Stock Forecast: Can the CAPTN-3 Platform Carry the Pipeline Into the Clinic?